This recombinant monoclonal antibody is developed as a research-grade biosimilar to Posdinemab, targeting microtubule-associated protein tau (MAPT). MAPT plays a critical role in stabilizing microtubules in neurons and regulating axonal transport. Under pathological conditions, tau undergoes hyperphosphorylation and aggregates into neurofibrillary tangles, a hallmark of Alzheimer's disease and other tauopathies including frontotemporal dementia, progressive supranuclear palsy, and chronic traumatic encephalopathy. Abnormal tau accumulation correlates with neurodegeneration and cognitive decline, making it a key therapeutic target in neurodegenerative disease research.
Posdinemab is a humanized monoclonal antibody designed to target pathological forms of tau protein and has been investigated in clinical trials for Alzheimer's disease. This biosimilar provides researchers with a valuable tool for studying tau biology, investigating tau-mediated neurotoxicity mechanisms, and evaluating potential therapeutic interventions in tauopathy models. It supports investigations into protein aggregation pathways, neuroinflammatory responses, and disease progression in neurodegenerative disorders.
Email: support@cusabio.com
Distributors Worldwide